Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration.
We have used a dynamic in-vitro model to determine the killing kinetics of two formulations of cefuroxime axetil against 18 clinical strains of Haemophilus influenzae. The concentration of cefuroxime axetil was adjusted dynamically to simulate the mean serum profile in healthy volunteers following the administration of a single 250 mg dose in oral suspension or tablet form. Bacterial numbers were reduced by 3 log10 cfu/mL during the eight-hour experimental period with both dosage form simulations. Our results suggest that cefuroxime axetil, 250 mg in oral suspension or tablet form, may protect against the dissemination of H. influenzae during episodes of bacteraemia.
Bingen
E
E
Service de Microbiologie, Hôpital Robert Debré, Paris, France.
Lambert-Zechovsky
N
N
Doit
C
C
Duvignaud
P
P
Georges
D
D
Mariani-Kurkdjian
P
P
D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D002444:Cefuroxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D002648:Child; D006193:Haemophilus influenzae / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008954:Models, Biological; D010033:Otitis Media / Q000382:microbiology; D013607:Tablets
D002214:Capsules; D013607:Tablets; D002444:Cefuroxime; C040738:cefuroxime axetil